This is the authors' abstract. We don't add key points for this paper.
Sea lice (Lepeophtheirus salmonis) infestations represent a challenge to Atlantic salmon (Salmo salar) aquaculture. We evaluated recombinant peroxinectin-like proteins (LsPxtl-1 and LsPxtl-2) and whole sea lice (WSL) crude proteins as vaccine antigens, administered intraperitoneally (i.p.) or via a combination of i.p./subcutaneous fin-base injection (IP-F). Fish were immunized, boosted, smoltified, and challenged with copepodites, and systemic (plasma) and mucosal (mucus) antibody responses were assessed alongside lice burden. LsPxtl-1 and IP-F vaccines reduced (p<0.05) lice counts compared to PBS controls. Elevated systemic IgM/IgT and IgT responses were observed, but levels did not correlate with lice reduction. Mucus antibody responses were generally weak, but suggest IgT may contribute to local protection, particularly in the IP-F group. Results demonstrate that antigen source and vaccine modality influence protection, and protective immunity likely involves additional mechanisms beyond measurable antibodies. Further optimization of antigens, formulations, and delivery strategies is required to achieve reliable vaccine-based control of salmon lice in aquaculture.
No takes yet. Share an insight, caveat, or question.
Gislefoss et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: